Literature DB >> 24186264

Stage II-IV lung cancer cases with lymphovascular invasion relapse within 2 years after surgery.

Satoshi Shiono1, Naoki Kanauchi, Naoki Yanagawa, Masami Abiko, Toru Sato.   

Abstract

OBJECTIVE: For recurrent lung cancer, postoperative follow-up methods have not been adequately assessed, and no evidence-based postoperative surveillance methods currently exist. Herein, we evaluated postoperative lung cancer recurrence and the personalized postoperative surveillance periods and methods used.
METHODS: Follow-up after surgery consisted of a regular outpatient clinic check-up, including physical examination, history, blood tests, and chest X-ray, which were conducted three or four times per year for 5 years. During the follow-up period, annual chest and brain computed tomography scanning was performed. Between May 2004 and December 2011, 547 lung cancer patients underwent complete resection in our institution. We retrospectively reviewed their prospectively collected data.
RESULTS: We selected 106 patients (19.4 %) who had a postoperative recurrence. Multivariate analysis showed that advanced stage (stage II-IV; p < 0.01) and lymphovascular invasion positivity (LVI; p = 0.01) were independent risk factors for earlier recurrence. Overall, 90.8 % of patients with advanced-stage disease and LVI positivity experienced a relapse within 2 years after surgery, compared to 55.1 % of patients who did not have these factors (p < 0.01). Multivariate analysis showed that recurrence with symptoms (p < 0.01) and shorter time to recurrence (<24 months; p < 0.01) were independent prognostic factors after recurrence.
CONCLUSIONS: Although this study was retrospective and included some biases, patients with advanced-stage lung cancer and LVI positivity should be intensively followed up. Personalized follow-up programs should be considered for lung cancer patients who have undergone resection.

Entities:  

Mesh:

Year:  2013        PMID: 24186264     DOI: 10.1007/s11748-013-0340-3

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  24 in total

1.  Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases.

Authors:  Romano Demicheli; Marco Fornili; Federico Ambrogi; Kristin Higgins; Jessamy A Boyd; Elia Biganzoli; Chris R Kelsey
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

2.  Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer.

Authors:  Yoshihisa Shimada; Hisashi Saji; Koichi Yoshida; Masatoshi Kakihana; Hidetoshi Honda; Masaharu Nomura; Jitsuo Usuda; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

3.  Results of long-term follow-up of patients with completely resected non-small cell lung cancer.

Authors:  Chiaki Endo; Akira Sakurada; Hirotsugu Notsuda; Masafumi Noda; Yasushi Hoshikawa; Yoshinori Okada; Takashi Kondo
Journal:  Ann Thorac Surg       Date:  2012-03-03       Impact factor: 4.330

Review 4.  Locoregional recurrence after pulmonary sublobar resection of non-small cell lung cancer: can it be reduced by considering cancer cells at the surgical margin?

Authors:  Noriyoshi Sawabata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-09-29

5.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

6.  Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer.

Authors:  Robert J Korst; Amanda L Kansler; Jeffrey L Port; Paul C Lee; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).

Authors:  Jeffrey Rubins; Michael Unger; Gene L Colice
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

9.  Post-treatment management options for patients with lung cancer.

Authors:  K S Virgo; L W McKirgan; M C Caputo; D M Mahurin; L C Chao; N A Caputo; K S Naunheim; M W Flye; K N Gillespie; F E Johnson
Journal:  Ann Surg       Date:  1995-12       Impact factor: 12.969

Review 10.  Follow-up and surveillance of the lung cancer patient following curative-intent therapy.

Authors:  Gene L Colice; Jeffrey Rubins; Michael Unger
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more
  3 in total

1.  Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence.

Authors:  Chanyeong Park; In Jae Lee; Seung Hun Jang; Jae Woong Lee
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.

Authors:  Tetsuya Isaka; Hiroyuki Ito; Tomoyuki Yokose; Haruhiro Saito; Hiroyuki Adachi; Kotaro Murakami; Jun Miura; Noritake Kikunishi; Yasushi Rino
Journal:  BMC Cancer       Date:  2022-09-09       Impact factor: 4.638

3.  Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.

Authors:  Xu-Dong Cheng; Jun-Fei Gu; Jia-Rui Yuan; Liang Feng; Xiao-Bin Jia
Journal:  Mol Med Rep       Date:  2015-10-15       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.